NEUROCRINE BIOSCIENCES INC - Common Stock (NBIX)

Historical Holders from Q1 2014 to Q4 2025

Type / Class: Equity / Common Stock
Symbol: NBIX on Nasdaq
Shares outstanding: 99,605,545
Price per share: $141.83
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares as of 30 Sep 2025: 96,832,070
Total reported value: $13,588,446,883
% of total 13F portfolios: 0.01%
Share change: -2,217,181
Value change: -$270,037,669
Avg buy value change: +0%
Avg sell value change: -0.01%
Number of holders: 636
Price from insider filings: $155.09

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of NEUROCRINE BIOSCIENCES INC - Common Stock (NBIX) based on Schedule 13D/G filings

Filer	Ownership	Holdings Value	Nb Shares	Reporting Name	Report Period
BlackRock, Inc.	12%	$1,095,189,866	12,052,271	BlackRock, Inc.	31 Mar 2025
VANGUARD GROUP INC	10%	$920,484,658	10,129,687	The Vanguard Group	28 Feb 2025
DODGE & COX	5.6%	$502,931,283	5,534,624	Dodge & Cox	31 Mar 2025
STATE STREET CORP	4.8%	$444,457,619	4,891,137	STATE STREET CORPORATION	31 Dec 2024

As of 30 Sep 2025, NEUROCRINE BIOSCIENCES INC - Common Stock (NBIX) has 636 institutional shareholders filing 13F forms. They hold 96,832,070 shares. of 99,605,545 outstanding shares (97%) .

Top 25 institutional shareholders own 65% of the company.

Filer	Ownership	Nb Shares	Share Change %	Portfolio %	Holdings Value
BlackRock, Inc.	13%	12,706,230	-1.9%	0.03%	$1,783,700,523
VANGUARD GROUP INC	9.7%	9,706,559	-1%	0.02%	$1,362,606,752
Dodge & Cox	5.6%	5,556,618	-0.18%	0.42%	$780,038,035
JPMORGAN CHASE & CO	4.7%	4,730,152	+11%	0.04%	$664,018,845
STATE STREET CORP	4.4%	4,346,479	-2.7%	0.02%	$610,158,722
PRICE T ROWE ASSOCIATES INC /MD/	2.9%	2,866,731	-7.1%	0.04%	$402,433,000
AQR CAPITAL MANAGEMENT LLC	2.8%	2,773,648	+84%	0.25%	$388,435,470
RENAISSANCE TECHNOLOGIES LLC	2.4%	2,418,297	+2.2%	0.45%	$339,480,533
GEODE CAPITAL MANAGEMENT, LLC	2%	2,024,825	+3.3%	0.02%	$283,499,084
MORGAN STANLEY	1.8%	1,826,936	+0.4%	0.02%	$256,465,385
WELLINGTON MANAGEMENT GROUP LLP	1.8%	1,811,762	-11%	0.04%	$254,335,149
Bellevue Group AG	1.8%	1,763,105	-3.1%	5.1%	$247,504,680
LOS ANGELES CAPITAL MANAGEMENT LLC	1.2%	1,202,756	+62%	0.57%	$168,842,887
DEERFIELD MANAGEMENT COMPANY, L.P.	1.2%	1,184,345	+1.4%	2.5%	$166,258,351
RTW INVESTMENTS, LP	1.1%	1,062,072	0%	1.8%	$149,093,667
MILLENNIUM MANAGEMENT LLC	0.98%	977,210	-18%	0.11%	$137,180,740
BNP PARIBAS ASSET MANAGEMENT Holding S.A.	0.95%	948,033	-8.2%	0.35%	$133,038,000
NORTHERN TRUST CORP	0.93%	925,714	-0.36%	0.02%	$129,951,731
BRAIDWELL LP	0.88%	880,282	-24%	3.7%	$123,573,987
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	0.83%	829,547	+5%	0.02%	$116,451,808
CITADEL ADVISORS LLC	0.8%	793,239	-61%	0.09%	$111,354,891
UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC	0.77%	765,237	-45%	0.02%	$107,423,971
Bank of New York Mellon Corp	0.76%	761,396	-2.2%	0.02%	$106,884,718
DIMENSIONAL FUND ADVISORS LP	0.71%	710,122	+3.8%	0.02%	$99,685,572
BANK OF AMERICA CORP /DE/	0.71%	704,254	+7.8%	0.01%	$98,863,177

Institutional Holders of NEUROCRINE BIOSCIENCES INC - Common Stock (NBIX) across Reporting Periods

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price (% of par)	Investors
2025 Q4	370,816	$52,259,548	+$25,931,346			14,182.97%	21
2025 Q3	96,832,070	$13,588,446,883	-$270,037,669	$66,820,880	$32,202,479	14,038%	636
2025 Q2	98,821,223	$12,420,454,326	+$494,179,758	$26,797,108	$36,284,759	12,569%	579
2025 Q1	95,417,971	$10,551,945,421	+$6,531,028	$56,041,131	$82,706,680	11,060%	576
2024 Q4	94,333,748	$12,873,973,627	+$277,419,295	$36,213,450	$38,400,362	13,650%	589
2024 Q3	92,618,112	$10,675,977,715	-$220,711,285	$66,551,072	$71,182,916	11,522%	567
2024 Q2	93,723,042	$12,899,413,706	+$111,362,329	$31,278,624	$90,848,233	13,767%	588
2024 Q1	92,893,700	$12,808,484,013	+$99,362,674	$47,371,521	$69,704,768	13,792%	578
2023 Q4	340,874	$44,922,763	-$4,661,614			13,176%	10
2023 Q3	91,624,177	$10,307,754,453	+$19,999,748	$46,340,712	$56,722,500	11,250%	498
2023 Q2	89,622,581	$8,456,259,836	+$8,430,809	$32,816,400	$34,532,660	9,430%	441
2023 Q1	90,680,694	$9,172,726,038	+$82,697,429	$22,885,842	$13,502,748	10,122%	472
2022 Q4	89,773,715	$10,712,889,415	+$124,934,670	$3,654,864	$13,219,176	11,944%	517
2022 Q3	89,171,673	$9,470,813,485	-$94,873,044	$4,408,000	$19,768,000	10,621%	441
2022 Q2	88,899,211	$8,661,032,375	-$6,400,984	$14,612,000	$49,339,000	9,748%	413
2022 Q1	86,505,431	$8,107,722,582	+$147,175,305	$65,551,000	$84,908,000	9,375%	401
2021 Q4	88,879,779	$7,563,734,979	-$135,795,395	$48,435,250	$41,528,000	8,516.97%	383
2021 Q3	89,939,974	$8,626,841,425	-$73,045,846	$34,849,750	$57,136,709	9,591%	381
2021 Q2	91,200,454	$8,874,238,168	-$391,326,180	$50,999,000	$70,113,084	9,731.97%	394
2021 Q1	94,776,648	$9,211,930,058	+$550,111,004	$44,772,054	$50,030,725	9,724.98%	404
2020 Q4	89,345,265	$8,564,242,432	-$6,526,498	$72,700,625	$30,259,675	9,584.95%	385
2020 Q3	88,443,291	$8,503,707,342	-$165,682,314	$86,044,000	$37,161,000	9,616.01%	399
2020 Q2	90,807,745	$11,093,067,640	+$57,420,368	$71,930,000	$73,117,000	12,200%	404
2020 Q1	90,430,403	$7,829,376,352	+$141,657,290	$47,325,000	$57,633,000	8,655.03%	353
2019 Q4	88,845,101	$9,547,614,883	-$105,647,998	$50,930,000	$88,803,000	10,748.98%	379
2019 Q3	89,544,054	$8,067,789,696	+$131,855,532	$54,128,000	$57,818,000	9,010.99%	320
2019 Q2	88,851,615	$7,501,057,970	+$476,297,870	$44,858,000	$69,927,000	8,443%	293
2019 Q1	88,273,975	$7,776,692,330	-$77,116,522	$63,800,000	$81,325,000	8,810%	318
2018 Q4	89,470,402	$6,374,594,256	-$87,239,322	$48,865,000	$73,636,000	7,140.89%	318
2018 Q3	88,623,711	$10,894,004,580	-$352,121,911	$81,893,000	$57,614,000	12,295.01%	337
2018 Q2	91,100,517	$8,948,547,815	+$108,689,438	$65,724,000	$65,462,000	9,823.97%	269
2018 Q1	92,034,159	$7,632,271,781	-$152,719,450	$53,951,000	$63,868,000	8,292.98%	258
2017 Q4	89,063,885	$6,910,330,345	-$127,768,371	$35,358,000	$29,018,000	7,759%	255
2017 Q3	95,975,362	$5,879,197,865	+$103,868,412	$23,030,000	$37,117,000	6,128%	219
2017 Q2	94,854,499	$4,360,456,382	+$625,150,488	$21,000,000	$15,163,000	4,600%	219
2017 Q1	84,832,216	$3,672,689,679	+$229,920,607	$11,842,000	$11,225,000	4,329.98%	212
2016 Q4	84,113,039	$3,255,240,619	-$79,497,227	$22,714,000	$18,388,000	3,870%	217
2016 Q3	85,700,381	$4,337,544,435	+$54,775,049	$6,274,000	$25,906,000	5,064%	235
2016 Q2	84,771,135	$3,855,815,900	-$118,002,301	$10,879,000	$68,138,000	4,545%	223
2016 Q1	87,598,920	$3,462,559,615	+$138,148,038	$12,571,000	$17,089,000	3,955%	208
2015 Q4	83,395,854	$4,717,623,664	+$48,341,852	$18,339,000	$20,542,000	5,656.99%	215
2015 Q3	82,777,737	$3,293,072,792	-$26,817,694	$17,664,000	$52,950,000	3,979%	202
2015 Q2	82,282,268	$3,929,380,654	-$83,608,659	$13,681,000	$48,635,000	4,775.99%	193
2015 Q1	85,169,622	$3,379,999,692	+$405,560,732	$16,312,000	$21,967,000	3,970.99%	170
2014 Q4	75,151,640	$1,678,834,423	+$53,080,878	$48,666,000	$13,224,000	2,233.98%	131
2014 Q3	73,295,238	$1,148,500,395	+$44,837,828	$16,377,000	$15,280,000	1,567.01%	132
2014 Q2	70,371,932	$1,044,160,097	+$24,609,151	$5,870,000	$6,404,000	1,483.82%	123
2014 Q1	69,736,034	$1,122,530,688	+$194,807,523	$6,456,000	$7,289,000	1,610%	121